✦ LIBER ✦

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study

✍ Scribed by Kim, S. C.; Schneeweiss, S.; Glynn, R. J.; Doherty, M.; Goldfine, A. B.; Solomon, D. H.

Book ID: 127036059
Publisher: BMJ Publishing Group
Year: 2014
Tongue: English
Weight: 941 KB
Volume: 74
Category: Article
ISSN: 0003-4967
DOI: 10.1136/annrheumdis-2014-205216

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acute Pancreatitis in Patients with Type

Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study

✍ Chou, Hsin-Chun; Chen, Wen-Wen; Hsiao, Fei-Yuan 📂 Article 📅 2014 🏛 Springer International Publishing AG 🌐 English ⚖ 263 KB

Metformin-inclusive sulfonylurea therapy

Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort

✍ Mark L. Wahlqvist; Meei-Shyuan Lee; Chih-Cheng Hsu; Shao-Yuan Chuang; Jiunn-Tay 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 351 KB

Metformin-inclusive sulfonylurea therapy

Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort

✍ Mark L. Wahlqvist; Meei-Shyuan Lee; Chih-Cheng Hsu; Shao-Yuan Chuang; Jiunn-Tay 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 351 KB

Objectives Type 2 diabetes (T2DM) may increase the risk of Parkinson's disease (PD). We evaluated the role of oral anti-hyperglycemic agents (OAA) in any diabetes–PD linkage. Methods From the Taiwan National Health Insurance database on 01-01-2000, a representative cohort of 800,000 was obtained be

A large scale population-based cohort st

A large scale population-based cohort study on the risk of ovarian neoplasm in patients with type 2 diabetes mellitus

✍ Chen, Hua-Fen; Chang, Ya-Hui; Ko, Ming-Chung; Li, Chung-Yi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 261 KB

Efficacy and safety of the dipeptidyl pe

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study*

✍ Pratley, Richard E.; Reusch, Jane E.-B.; Fleck, Penny R.; Wilson, Craig A.; Mekk 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 282 KB

Pharmacokinetic, pharmacodynamic, and to

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

✍ Paul Covington; Ronald Christopher; Michael Davenport; Penny Fleck; Qais A. Mekk 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 253 KB